Abstract
To estimate the annual impact of the inclusion of nonacog beta pegol in the Colombian health system for the prophylaxis treatment of previously treated patients with a confirmed diagnosis of haemophilia B.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
